These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 33971289)

  • 1. Association Between β-Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry.
    Meyer M; Du Fay Lavallaz J; Benson L; Savarese G; Dahlström U; Lund LH
    J Card Fail; 2021 Nov; 27(11):1165-1174. PubMed ID: 33971289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry.
    Stolfo D; Uijl A; Benson L; Schrage B; Fudim M; Asselbergs FW; Koudstaal S; Sinagra G; Dahlström U; Rosano G; Savarese G
    Eur J Heart Fail; 2020 Jan; 22(1):103-112. PubMed ID: 31478583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M; Friberg L
    JAMA; 2014 Nov; 312(19):2008-18. PubMed ID: 25399276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
    Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
    Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction.
    Arnold SV; Silverman DN; Gosch K; Nassif ME; Infeld M; Litwin S; Meyer M; Fendler TJ
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):893-900. PubMed ID: 37140513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
    Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
    JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate.
    Lam PH; Gupta N; Dooley DJ; Singh S; Deedwania P; Zile MR; Bhatt DL; Morgan CJ; Pitt B; Fonarow GC; Ahmed A
    Am J Med; 2018 Dec; 131(12):1473-1481. PubMed ID: 30076815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Sartipy U; Dahlström U; Fu M; Lund LH
    JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M
    JAMA; 2012 Nov; 308(20):2108-17. PubMed ID: 23188027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial.
    Peikert A; Bart BA; Vaduganathan M; Claggett BL; Kulac IJ; Kosiborod MN; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD; Vardeny O
    JACC Heart Fail; 2024 Apr; 12(4):631-644. PubMed ID: 37767674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction.
    Park CS; Park JJ; Mebazaa A; Oh IY; Park HA; Cho HJ; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
    J Am Heart Assoc; 2019 Mar; 8(6):e011077. PubMed ID: 30845873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of heart rate changes during hospitalization on outcome in heart failure with preserved ejection fraction.
    Liu D; Cui X; Xu Y; Xu L; Xie Z; Yuan S; Wang P; Wang Y; Qian S; Gong H; Nordbeck P; Yang J; Zhou J; Ge J; Sun A
    ESC Heart Fail; 2024 Oct; 11(5):2901-2912. PubMed ID: 38514992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial Strain for Identification of β-Blocker Responders in Heart Failure with Preserved Ejection Fraction.
    Park JJ; Choi HM; Hwang IC; Park JB; Park JH; Cho GY
    J Am Soc Echocardiogr; 2019 Nov; 32(11):1462-1469.e8. PubMed ID: 31540679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to beta-blockers and natriuretic peptide level in acute heart failure: analysis of data from the Korean acute heart failure registry.
    Park CS; Park JJ; Mebazaa A; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
    Clin Res Cardiol; 2021 Sep; 110(9):1392-1403. PubMed ID: 32588127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
    Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
    Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry.
    Settergren C; Benson L; Shahim A; Dahlström U; Thorvaldsen T; Savarese G; Lund LH; Shahim B
    Eur J Heart Fail; 2024 May; 26(5):1150-1159. PubMed ID: 38606645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes.
    Patel K; Fonarow GC; Ekundayo OJ; Aban IB; Kilgore ML; Love TE; Kitzman DW; Gheorghiade M; Allman RM; Ahmed A
    Int J Cardiol; 2014 May; 173(3):393-401. PubMed ID: 24703206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.